Find out why FDA’s complete response letter for Corcept’s relacorilant could reshape treatment of hypercortisolism, with implications for oncology approval.
Explore what global spondyloarthritis trial trends in 2025 reveal about innovation gaps, sponsor risk, and regulatory hurdles. Read the full industry analysis.
New subgroup data on HEPZATO highlights improved survival in low-burden metastatic uveal melanoma. Find out what this changes in clinical strategy.
GSK plc’s latest agreement with the United States Administration to lower the price of respiratory medicines, including its inhaled asthma and chronic obstructive pulmonary disease (COPD) portfolio, signals a shift in how global pharmaceutical companies are choosing to respond to increasing U.S. political pressure around drug affordability. The agreement, announced on December 22, 2025, satisfies […]
A representative image depicting natural supplement capsules, reinforcing the rise of clinically formulated nutraceuticals like MyBladder® in urological wellness.
NEREUS becomes first FDA-approved motion sickness drug in 40 years. Find out how this approval could reshape antiemetic strategies across industries.
Overture Orthopaedics hits $1M in sales for its knee resurfacing system targeting early OA. Find out what this milestone reveals about joint preservation.
Find out how Lumos Infinitas’ photonics platform could shift clinical sensing and where adoption hurdles remain. Read analysis and expert insight.
Mabwell doses first patient in Phase II trial of IL-11 antibody for pathological scarring. Find out what this means for fibrosis drug development.
HAI Solutions has received De Novo classification from the U.S. Food and Drug Administration (FDA) for its QIKCAP System, making it the first ultraviolet light-based microbial reduction device to be granted such approval for use with needleless luer-activated IV connectors. The FDA decision establishes a new Class II medical device category, placing the QIKCAP platform […]